231 related articles for article (PubMed ID: 29915289)
21. Loci of intestinal distress in cystic fibrosis knockout mice.
Haston CK; Tsui LC
Physiol Genomics; 2003 Jan; 12(2):79-84. PubMed ID: 12441405
[TBL] [Abstract][Full Text] [Related]
22. Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome.
Bazett M; Honeyman L; Stefanov AN; Pope CE; Hoffman LR; Haston CK
Mamm Genome; 2015 Jun; 26(5-6):222-34. PubMed ID: 25721416
[TBL] [Abstract][Full Text] [Related]
23. Very mild disease phenotype of congenic CftrTgH(neoim)Hgu cystic fibrosis mice.
Tóth B; Wilke M; Stanke F; Dorsch M; Jansen S; Wedekind D; Charizopoulou N; Bot A; Burmester M; Leonhard-Marek S; de Jonge HR; Hedrich HJ; Breves G; Tümmler B
BMC Genet; 2008 Apr; 9():28. PubMed ID: 18400105
[TBL] [Abstract][Full Text] [Related]
24. CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR.
Wang Y; Liu J; Loizidou A; Bugeja LA; Warner R; Hawley BR; Cai Z; Toye AM; Sheppard DN; Li H
Br J Pharmacol; 2014 Oct; 171(19):4490-503. PubMed ID: 24902474
[TBL] [Abstract][Full Text] [Related]
25. Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.
De Lisle RC; Mueller R; Roach E
BMC Gastroenterol; 2010 Sep; 10():107. PubMed ID: 20843337
[TBL] [Abstract][Full Text] [Related]
26. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
27. The CF-modifying gene EHF promotes p.Phe508del-CFTR residual function by altering protein glycosylation and trafficking in epithelial cells.
Stanke F; van Barneveld A; Hedtfeld S; Wölfl S; Becker T; Tümmler B
Eur J Hum Genet; 2014 May; 22(5):660-6. PubMed ID: 24105369
[TBL] [Abstract][Full Text] [Related]
28. Molecular pathophysiology of cystic fibrosis based on the rescued knockout mouse model.
Cohen JC; Morrow SL; Cork RJ; Delcarpio JB; Larson JE
Mol Genet Metab; 1998 Jun; 64(2):108-18. PubMed ID: 9705235
[TBL] [Abstract][Full Text] [Related]
29. Genetic analysis of Rwandan patients with cystic fibrosis-like symptoms: identification of novel cystic fibrosis transmembrane conductance regulator and epithelial sodium channel gene variants.
Mutesa L; Azad AK; Verhaeghe C; Segers K; Vanbellinghen JF; Ngendahayo L; Rusingiza EK; Mutwa PR; Rulisa S; Koulischer L; Cassiman JJ; Cuppens H; Bours V
Chest; 2009 May; 135(5):1233-1242. PubMed ID: 19017867
[TBL] [Abstract][Full Text] [Related]
30. Iron Homeostasis and Inflammatory Status in Mice Deficient for the Cystic Fibrosis Transmembrane Regulator.
Deschemin JC; Allouche S; Brouillard F; Vaulont S
PLoS One; 2015; 10(12):e0145685. PubMed ID: 26709821
[TBL] [Abstract][Full Text] [Related]
31. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
[TBL] [Abstract][Full Text] [Related]
32. Lung disease modifier genes in cystic fibrosis.
Guillot L; Beucher J; Tabary O; Le Rouzic P; Clement A; Corvol H
Int J Biochem Cell Biol; 2014 Jul; 52():83-93. PubMed ID: 24569122
[TBL] [Abstract][Full Text] [Related]
33. Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells.
Penque D; Mendes F; Beck S; Farinha C; Pacheco P; Nogueira P; Lavinha J; Malhó R; Amaral MD
Lab Invest; 2000 Jun; 80(6):857-68. PubMed ID: 10879737
[TBL] [Abstract][Full Text] [Related]
34. Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity.
Paranjapye A; Ruffin M; Harris A; Corvol H
J Cyst Fibros; 2020 Mar; 19 Suppl 1(Suppl 1):S10-S14. PubMed ID: 31734115
[TBL] [Abstract][Full Text] [Related]
35. Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D-CFTR.
Xu Z; Pissarra LS; Farinha CM; Liu J; Cai Z; Thibodeau PH; Amaral MD; Sheppard DN
J Physiol; 2014 May; 592(9):1931-47. PubMed ID: 24591578
[TBL] [Abstract][Full Text] [Related]
36. Intestinal phenotype of variable-weight cystic fibrosis knockout mice.
Canale-Zambrano JC; Poffenberger MC; Cory SM; Humes DG; Haston CK
Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G222-9. PubMed ID: 17615178
[TBL] [Abstract][Full Text] [Related]
37. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E
J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768
[TBL] [Abstract][Full Text] [Related]
38. Molecular Genetics of Cystic Fibrosis Transmembrane Conductance Regulator: Genotype and Phenotype.
Sosnay PR; Raraigh KS; Gibson RL
Pediatr Clin North Am; 2016 Aug; 63(4):585-98. PubMed ID: 27469177
[TBL] [Abstract][Full Text] [Related]
39. Detection of F508del mutation in cystic fibrosis transmembrane conductance regulator gene mutation among Malays.
Zilfalil BA; Sarina S; Liza-Sharmini AT; Oldfield NJ; Stenhouse SA
Singapore Med J; 2006 Feb; 47(2):129-33. PubMed ID: 16435054
[TBL] [Abstract][Full Text] [Related]
40. Genotype and phenotype in cystic fibrosis.
Zielenski J
Respiration; 2000; 67(2):117-33. PubMed ID: 10773783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
